[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"conditionNormalized\":\"frostbite\",\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:frostbite":29},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,4,0,[8,78,106,133],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":14,"acronym":4,"eligibilityCriteria":15,"healthyVolunteers":11,"sex":16,"minAge":4,"maxAge":4,"enrollmentInfo":17,"targetDuration":4,"studyType":20,"phases":21,"briefSummary":23,"conditions":24,"keywords":4,"overallStatus":66,"whyStopped":4,"lastUpdateSubmitDate":67,"lastUpdatePostDateStruct":68,"startDateStruct":71,"completionDateStruct":73,"leadSponsor":75,"locationsCount":4},"100611443","phase-4-outcomes-from-hyperbaric-oxygen-hbo2-treatment-for-emerging-indications-100611443",false,"NCT07240649","Outcomes From Hyperbaric Oxygen (HBO2) Treatment for Emerging Indications","Emerging Indications for Hyperbaric Oxygen Treatment","Inclusion Criteria:\n\n* Patients referred for HBOT with an emerging indication\n\nExclusion Criteria:\n\n* Contraindication to hyperbaric oxygen treatment (untreated seizures, pneumothorax, significant pulmonary airspace pathology that might lead to pulmonary barotrauma, unmanageable confinement anxiety, chronic obstructive pulmonary disease with CO2 retention)\n* Pregnant persons","ALL",{"count":18,"type":19},100,"ESTIMATED","INTERVENTIONAL",[22],"PHASE4","This study will evaluate the effectiveness of hyperbaric oxygen therapy (HBOT) on treating emerging indications (i.e., conditions that have shown to potentially benefit from HBOT) using the Multicenter Registry for Hyperbaric Oxygen Treatment. The study team aims to collect ongoing data on how well HBOT treats these emerging indications, and to add these data to the growing HBO Registry. The research team hypothesizes that HBOT will result in improvements of the condition of the various emerging indications.",[25,26,27,28,29,30,31,32,33,34,35,36,37,38,39,40,41,42,43,44,45,46,47,48,49,50,51,52,53,54,55,56,57,58,59,60,61,62,63,64,65],"Post-COVID-19 Condition","Ulcerative Colitis","Crohn Disease","Calciphylaxis","Frostbite","Acute COVID-19","Pyoderma Gangrenosum","Pterygium","Hypospadias","Head Trauma","Pneumatosis Intestinalis","Ischemic Bowel","Raynaud Syndrome","Malignant Otitis Externa","Nonarteritic Anterior Ischemic Optic Neuropathy","Central Retinal Vein Occlusion","Femoral Head Necrosis","Invasive Fungal Infection","Chronic Anal Fissure","Vasculitic Ulcer","Graft-vs-Host Disease","Decubitus Ulcer","Greater Trochanteric Pain Syndrome","Rectovaginal Fistula","Pouchitis","Tinnitus","Clostridium Enterocolitis","Branch Retinal Artery Occlusion","Axonotmesis","Multiple Sclerosis","Inclusion Body Myositis","Epidermolysis Bullosa (EB)","Osteonecrosis","Ulcer Ischemic","Avascular Necrosis of Bone","Prosthesis Related Infections","Facial Filler Injections","Cystitis Chronic","Ligament Injury","Anastomosis, Leaking","Cartilage Injury","NOT_YET_RECRUITING","2026-05-01",{"date":69,"type":70},"2026-05-05","ACTUAL",{"date":72,"type":19},"2026-08",{"date":74,"type":19},"2035-12",{"name":76,"class":77},"Jay C. Buckey Jr.","OTHER",{"id":79,"slug":80,"hasResults":11,"nctId":81,"briefTitle":82,"officialTitle":83,"acronym":84,"eligibilityCriteria":85,"healthyVolunteers":11,"sex":16,"minAge":86,"maxAge":4,"enrollmentInfo":87,"targetDuration":4,"studyType":89,"phases":4,"briefSummary":90,"conditions":91,"keywords":94,"overallStatus":66,"whyStopped":4,"lastUpdateSubmitDate":96,"lastUpdatePostDateStruct":97,"startDateStruct":99,"completionDateStruct":101,"leadSponsor":103,"locationsCount":105},"100627579","field-study-on-intravenous-iloprost-for-treatment-of-severe-frostbite-at-high-altitude-100627579","NCT07450469","Field Study on Intravenous Iloprost for Treatment of Severe Frostbite at High Altitude","High-Altitude Iloprost Feasibility Study for Treatment of Frostbite","HAI-Frost","Inclusion Criteria:\n\n* Frostbite grade 3\u002F4 eligible for Iloprost\n* \\\u003C72h of thawing\n* min. age of 18 years\n* provision of written informed consent\n\nExclusion Criteria:\n\n* age \\\u003C18 years\n* general contraindication\n* pregnancy\n* inability\u002Fdenial to provide informed consent","18 Years",{"count":88,"type":19},10,"OBSERVATIONAL","The goal of this observational study is to learn whether intravenous iloprost treatment for severe frostbite (grades 3-4) is feasible and safe when delivered in pre-hospital, remote high-altitude settings.\n\nThe main questions it aims to answer are:\n\n* Is it feasible to initiate and deliver guideline-based intravenous iloprost for grade 3-4 frostbite at high altitude and what logistical barriers arise?\n* Does field-based initiation of iloprost increase tissue preservation and reduce amputations (compared to historical cases from similar settings)?\n\nParticipants receiving Iloprost as part of a frostbite treatment will be followed up after discharge as well as 6, 12 and 18 months to assess tissue preservation and long-term sequelae from the initial frostbite injury.",[29,92,93],"Altitude","Field Physician Care",[95],"iloprost","2026-03-05",{"date":98,"type":70},"2026-03-09",{"date":100,"type":19},"2026-05",{"date":102,"type":19},"2028-05",{"name":104,"class":77},"Institute of Mountain Emergency Medicine",1,{"id":107,"slug":108,"hasResults":11,"nctId":109,"briefTitle":110,"officialTitle":111,"acronym":112,"eligibilityCriteria":113,"healthyVolunteers":11,"sex":16,"minAge":86,"maxAge":4,"enrollmentInfo":114,"targetDuration":4,"studyType":20,"phases":116,"briefSummary":117,"conditions":118,"keywords":119,"overallStatus":66,"whyStopped":4,"lastUpdateSubmitDate":123,"lastUpdatePostDateStruct":124,"startDateStruct":126,"completionDateStruct":128,"leadSponsor":130,"locationsCount":132},"100625572","phase-4-epoprostenol-plus-conventional-therapy-in-cold-and-frostbite-injury-ecco-100625572","NCT07424378","Epoprostenol Plus Conventional Therapy in COld and Frostbite Injury (ECCO)","Randomized Controlled Trial of Epoprostenol Versus Placebo in Addition to Standard Therapy for Severe Frostbite Injury","ECCO","Inclusion Criteria:\n\n1. Aged ≥ 18 years\n2. Admitted to University of Colorado Hospital (UCH) Burn and Frostbite Center\n3. Cauchy Grade 2-4 frostbite injury\n4. Admission within 72 hours post-rewarming\n\nExclusion Criteria:\n\n1. Patients unable to initiate therapy within 72 hours post-rewarming\n2. Unsalvageable frostbite as defined by obvious necrosis of tissue, wet gangrene, or other condition requiring amputation (within the first week)\n3. Anticipated death within 48 hours of admission\n4. Pregnant or breastfeeding patients\n5. Prisoners\n6. Inability to obtain consent from patient or legally authorized representative (LAR) or proxy\n7. Not a good candidate for treatment per treating physician or investigator\n8. Patients with known allergy\u002Fhypersensitivity to epoprostenol\n9. Current or planned receipt of other prostaglandin analog (iloprost and treprostinil)\n10. Known congestive heart failure due to severe left ventricular systolic dysfunction (New York Heart Association (NYHA) class III\u002FIV)\n11. Known right heart failure (RHF)\n12. Hypotension unresponsive to fluids and discontinuation of concomitant anti-hypertensives (mean arterial pressure (MAP) \\\u003C 65 mmHg)\n13. Known pulmonary hypertension",{"count":115,"type":19},66,[22],"Severe frostbite injury can result in significant lifelong disability and amputation. Various medicines, including intravenous vasodilators (prostaglandins\u002Filoprost, pentoxifylline, buflomedil) along with thrombolytics (alteplase), have been described to counter tissue ischemia after rewarming, with poor quality of evidence. An in-class prostacyclin, epoprostenol, has similar pharmacodynamic properties to iloprost including vasodilation and platelet inhibition and has been used in peripheral tissue ischemia such as Raynaud's and scleroderma. In this trial, we will evaluate the effectiveness and safety of epoprostenol treatment for severe frostbite injury in addition to standard of care.",[29],[29,120,121,122],"Epoprostenol","Prostaglandin","Amputation","2026-02-19",{"date":125,"type":70},"2026-02-20",{"date":127,"type":19},"2026-02",{"date":129,"type":19},"2028-11",{"name":131,"class":77},"University of Colorado, Denver",2,{"id":134,"slug":135,"hasResults":11,"nctId":136,"briefTitle":137,"officialTitle":137,"acronym":29,"eligibilityCriteria":138,"healthyVolunteers":139,"sex":16,"minAge":86,"maxAge":140,"enrollmentInfo":141,"targetDuration":4,"studyType":20,"phases":142,"briefSummary":143,"conditions":144,"keywords":4,"overallStatus":145,"whyStopped":4,"lastUpdateSubmitDate":146,"lastUpdatePostDateStruct":147,"startDateStruct":149,"completionDateStruct":151,"leadSponsor":152,"locationsCount":105},"100536566","phase-4-prevention-and-treatment-of-frostbite-infection-with-antimicrobial-pharmacokinetic-analysis-100536566","NCT06266494","Prevention and Treatment of Frostbite Infection With Antimicrobial Pharmacokinetic Analysis","Inclusion Criteria:\n\n* All aims, aged ≥18 - \\\u003C 99 years old admitted to UCH Burn Center with frostbite injury\n* Aim 1: Admitted to UCH Burn Center with acute (within 4 days of cold exposure) frostbite injury\n* Aim 2: Admitted to UCH Burn center with a clinically confirmed or suspected infected frostbite wound\n\nExclusion Criteria:\n\n* Pregnant patients\n* Prisoners\n* Anticipated death within 48 hours of admission\n* Inability to obtain consent from patient, legally authorized representative, or proxy\n* Aim 1:Patients admitted five days and later from frostbite injury. Patients who have a clinical infection at baseline. Any patients that have a contra-indication for the use of either aloe (allergy), or silver (allergy).\n* Aim 2: Any patients that have a contraindication for use of dalbavancin, including known history of hypersensitivity to dalbavancin, vancomycin, or other glycopeptide antibiotics. Patients with infections known to be caused by vancomycin-resistant Enterococcus; or those with Stage IV or V chronic kidney disease, or with cirrhosis (Childs-Pugh C); or those with anticipated death within 48 hours of infection.\n* Aim 3: Anuria due to chronic kidney disease (CKD)",true,"99 Years",{"count":18,"type":19},[22],"This study will compare the effectiveness of two different treatments for preventing infection from frostbite injuries. These two treatments are A) aloe vera and B) long-acting silver wound dressings. The investigators will also study the safety and effectiveness of Dalbavancin, an FDA approved antibiotic used for treating people who develop frostbite wound infections, as well as evaluate how frostbite damage to individuals' bodies may affect how fast their kidney clear drugs from their systems.",[29],"RECRUITING","2024-05-10",{"date":148,"type":70},"2024-05-13",{"date":150,"type":70},"2024-03-01",{"date":72,"type":19},{"name":131,"class":77}]